2. Immunology/Inflammation NF-κB Metabolic Enzyme/Protease Cell Cycle/DNA Damage Vitamin D Related/Nuclear Receptor Stem Cell/Wnt MAPK/ERK Pathway Membrane Transporter/Ion Channel Apoptosis
  3. COX NF-κB PPAR ERK GLUT Apoptosis
  4. Avicularin

Avicularin is an orally active flavonoid. Avicularin inhibits NF-κB (p65), COX-2 and PPAR-γ activities. Avicularin has anti-inflammatory, anti-infectious anti-allergic, anti-oxidant, hepatoprotective, and anti-tumor activities.

For research use only. We do not sell to patients.

Avicularin Chemical Structure

Avicularin Chemical Structure

CAS No. : 572-30-5

Size Price Stock Quantity
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 192 In-stock
Solution
10 mM * 1 mL in DMSO USD 192 In-stock
Solid
1 mg USD 83 In-stock
5 mg USD 175 In-stock
10 mg USD 260 In-stock
25 mg USD 475 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

Other Forms of Avicularin:

Avicularin Related Antibodies

Top Publications Citing Use of Products

    Avicularin purchased from MedChemExpress. Usage Cited in: J Agric Food Chem. 2022 Dec 20.  [Abstract]

    Avicularin (AL; 10, 100, 300 μM) decreases F-actin ring size and number and nuclei count in a dose-dependent manner.

    Avicularin purchased from MedChemExpress. Usage Cited in: J Agric Food Chem. 2022 Dec 20.  [Abstract]

    Avicularin (AL; 100 μM; 0, 10, 20, 30, and 60 min) disrupts RANKL-induced osteoclast differentiation by inhibiting the NF-κB signaling pathway (Fig A). Avicularin (AL; 100 μM; 0, 10, 20, 30, and 60 min) also disrupts IκBα phosphorylation and degradation (Fig B–D).

    Avicularin purchased from MedChemExpress. Usage Cited in: J Agric Food Chem. 2022 Dec 20.  [Abstract]

    Avicularin (AL; 10, 30, 100, 300 μM; 5 days) disrupts RANKL-induced osteoclastogenesis in vitro. Representative image of in vitro TRAP staining.

    View All COX Isoform Specific Products:

    View All Isoforms

    View All NF-κB Isoform Specific Products:

    View All Isoforms

    View All PPAR Isoform Specific Products:

    View All Isoforms

    View All ERK Isoform Specific Products:

    View All Isoforms

    View All GLUT Isoform Specific Products:

    View All Isoforms

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Avicularin is an orally active flavonoid. Avicularin inhibits NF-κB (p65), COX-2 and PPAR-γ activities. Avicularin has anti-inflammatory, anti-infectious anti-allergic, anti-oxidant, hepatoprotective, and anti-tumor activities[1][3].

    IC50 & Target[2][3]

    GLUT4

     

    PPARγ

     

    COX-2

     

    In Vitro

    Avicularin (10-300 μM, 1 h) suppresses NO and PGE2 production in LPS-stimulated RAW 264.7 cells[1].
    Avicularin (10-300 μM, 1 h) exhibits anti-inflammatory activity through the suppression of ERK signaling pathway in LPS-stimulated RAW 264.7 cells[1].
    Avicularin (25-100 μg/mL, 48 h) decreases cell proliferation, cell migration and invasion in Huh7 cells[2].
    Avicularin (25-100 μg/mL, 48 h) induces apoptosis via the downregulation of NF‑κB (p65) and COX‑2 and the upregulation of PPAR‑γ[2].
    Avicularin (50 μM, 6 days) decreases the intracellular lipids, along with decreased PPARγ, C/EBPα, and aP2 mRNA levels in 3T3-L1 cells[3].
    Avicularin (50 μM, 6 days) suppresses GLUT4-Mediated glucose uptake in 3T3-L1 cells[3].
    Avicularin (2.5-10 μM, 2 h) inhibits ECM degradation and inflammation via TRAF6/MAPK activation in rat and human chondrocytes[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Avicularin Related Antibodies

    Cell Proliferation Assay[2]

    Cell Line: Huh7 cells
    Concentration: 25, 50, 100 μg/mL
    Incubation Time: 12, 24, 36 and 48 h
    Result: Inhibited cell proliferation in a dose-dependent manner.

    Western Blot Analysis[1]

    Cell Line: RAW 264.7 cells
    Concentration: 10, 30, 100, 300 μM
    Incubation Time: 1 h
    Result: Inhibited LPS-induced protein expression of iNOS and COX-2, release of pro-inflammatory cytokine IL-1β, degradation of cytosolic IκB, and phosphorylation of ERK.

    RT-PCR[3]

    Cell Line: 3T3-L1 cells
    Concentration: 50 μM
    Incubation Time: 6 days
    Result: Decreased PPARγ, C/EBPα, and aP2 mRNA levels approximately 28.7, 69.5, and 18.3%, respectively.
    In Vivo

    Avicularin (injected in articular cavity of the knee, 0.5-2 mg/kg, twice a week for 4 weeks) attenuates the development of OA (osteoarthritis) in ACLT-induced rats[4].
    Avicularin (oral administration, 50 and 100 mg/kg, for 21 days) attenuates memory Impairment in rats with amyloid Beta-induced Alzheimer's disease[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: ACLT (anterior cruciate ligament transection)-induced rats[4]
    Dosage: 0.5, 1, 2 mg/kg
    Administration: Injected into the articular cavity of the right knee, twice a week for 4 weeks.
    Result: Alleviated the tibial subchondral osteolysis, reduces bone loss, and increases the bone mass of tibial subchondral bone.
    Attenuated ECM degradation, the loss of Aggrecan and Collagen II in ACLT-induced rats.
    Decreased the MMP3 and MMP13 protein level.
    Animal Model: Rats with amyloid Beta-induced Alzheimer's disease[5]
    Dosage: 25, 50, and 100 mg/kg
    Administration: Oral administration, for 21 days
    Result: Enhanced cognition activity, and reversed the effects of amyloid beta-induced inflammatory response and excessive oxidative stress.
    Molecular Weight

    434.35

    Formula

    C20H18O11
    CAS No.
    Appearance

    Solid

    Color

    Light yellow to yellow

    SMILES

    O=C1C(O[C@H]2[C@@H]([C@H]([C@H](CO)O2)O)O)=C(C3=CC=C(O)C(O)=C3)OC4=CC(O)=CC(O)=C14
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (230.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.3023 mL 11.5115 mL 23.0229 mL
    5 mM 0.4605 mL 2.3023 mL 4.6046 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.48%

    COA (260 KB) HNMR (472 KB) RP-HPLC (142 KB) MS (84 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.3023 mL 11.5115 mL 23.0229 mL 57.5573 mL
    5 mM 0.4605 mL 2.3023 mL 4.6046 mL 11.5115 mL
    10 mM 0.2302 mL 1.1511 mL 2.3023 mL 5.7557 mL
    15 mM 0.1535 mL 0.7674 mL 1.5349 mL 3.8372 mL
    20 mM 0.1151 mL 0.5756 mL 1.1511 mL 2.8779 mL
    25 mM 0.0921 mL 0.4605 mL 0.9209 mL 2.3023 mL
    30 mM 0.0767 mL 0.3837 mL 0.7674 mL 1.9186 mL
    40 mM 0.0576 mL 0.2878 mL 0.5756 mL 1.4389 mL
    50 mM 0.0460 mL 0.2302 mL 0.4605 mL 1.1511 mL
    60 mM 0.0384 mL 0.1919 mL 0.3837 mL 0.9593 mL
    80 mM 0.0288 mL 0.1439 mL 0.2878 mL 0.7195 mL
    100 mM 0.0230 mL 0.1151 mL 0.2302 mL 0.5756 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Avicularin Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Avicularin572-30-5COXNF-κBPPARERKGLUTApoptosisCyclooxygenaseNuclear factor-κBNuclear factor-kappaBPeroxisome proliferator-activated receptorsExtracellular signal regulated kinasesGlucose transporter HCCinflammationRAW 264.7macrophagesoxidative stressLPSadipocytes3T3-L1lipidsECMosteoarthritisAlzheimer’s diseaseADInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Avicularin
    Cat. No.:
    HY-N0222
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.